Key result
Prior cardiovascular disease, lower eGFR, and lower serum albumin were associated with higher plasma CXCL16 levels.
Why the study?
What are the predictors of circulating CXCL16 levels in patients with diabetic kidney disease?
Cross-Sectional (n=134)
What are the predictors of circulating CXCL16 levels in patients with diabetic kidney disease?
In patients with diabetic kidney disease, lower eGFR and serum albumin independently predict higher plasma CXCL16 levels, which are also elevated in those with prior cardiovascular disease.
Answers are grounded in this paper and cite their sources.
May inform vascular risk monitoring in diabetic kidney disease; leaves open CXCL16 as therapeutic target.
BACKGROUND/AIMS: Chronic kidney disease and, specifically, diabetic kidney disease, is among the fastest increasing causes of death worldwide. A better understanding of the factors contributing to the high mortality may help design novel monitoring and therapeutic approaches. CXCL16 is both a cholesterol receptor and a chemokine with a potential role in vascular injury and inflammation. We aimed at identifying predictors of circulating CXCL16 levels in diabetic patients with chronic kidney disease. METHODS: We have now studied plasma CXCL16 in 134 European patients with diabetic kidney disease with estimated glomerular filtration rate (eGFR) categories G1-G4 and albuminuria categories A1-A3, in order to identify factors influencing plasma CXCL16 in this population. RESULTS: Plasma CXCL16 levels were 4.0±0.9 ng/ml. Plasma CXCL16 increased with increasing eGFR category from G1 to G4 (that is, with decreasing eGFR values) and with increasing albuminuria category. Plasma CXCL16 was higher in patients with prior cardiovascular disease (4.33±1.03 vs 3.88±0.86 ng/ml; p=0.013). In multivariate analysis, eGFR and serum albumin had an independent and significant negative correlation with plasma CXCL16. CONCLUSION: In diabetic kidney disease patients, GFR and serum albumin independently predicted plasma CXCL16 levels.
No takes yet. Share an insight, caveat, or question.
Elewa et al. (2016) conducted a cross-sectional in Diabetic kidney disease (n=134). Prior cardiovascular disease, eGFR, and serum albumin vs. No prior cardiovascular disease was evaluated on Plasma CXCL16 levels (p=0.013). Prior cardiovascular disease, lower eGFR, and lower serum albumin were associated with higher plasma CXCL16 levels.
Synapse has enriched 10 related papers. Consider them for comparative context: